Nightstar Therapeutics PLC Sponsored ADR (NASDAQ:NITE) Earns Outperform Rating from Analysts at Leerink Swann

Equities researchers at Leerink Swann initiated coverage on shares of Nightstar Therapeutics PLC Sponsored ADR (NASDAQ:NITE) in a research report issued on Monday, October 23rd, MarketBeat reports. The brokerage set an “outperform” rating and a $25.00 price target on the stock. Leerink Swann’s price objective would suggest a potential upside of 24.94% from the company’s current price. Leerink Swann also issued estimates for Nightstar Therapeutics PLC Sponsored ADR’s Q3 2017 earnings at ($0.12) EPS, Q4 2017 earnings at ($0.17) EPS, FY2017 earnings at ($0.70) EPS, FY2018 earnings at ($1.30) EPS and FY2019 earnings at ($1.27) EPS.

A number of other research firms have also commented on NITE. Wedbush assumed coverage on Nightstar Therapeutics PLC Sponsored ADR in a research note on Monday, October 23rd. They set an “outperform” rating and a $19.00 price objective on the stock. Jefferies Group LLC assumed coverage on Nightstar Therapeutics PLC Sponsored ADR in a research note on Monday, October 23rd. They set a “buy” rating and a $25.00 price objective on the stock. Finally, BMO Capital Markets assumed coverage on Nightstar Therapeutics PLC Sponsored ADR in a research note on Monday, October 23rd. They set an “outperform” rating and a $30.00 price objective on the stock.

Nightstar Therapeutics PLC Sponsored ADR (NASDAQ NITE) traded down $1.29 during trading on Monday, reaching $20.01. The company’s stock had a trading volume of 96,100 shares, compared to its average volume of 103,458. Nightstar Therapeutics PLC Sponsored ADR has a 12-month low of $14.56 and a 12-month high of $24.93.

ILLEGAL ACTIVITY NOTICE: “Nightstar Therapeutics PLC Sponsored ADR (NASDAQ:NITE) Earns Outperform Rating from Analysts at Leerink Swann” was originally reported by BBNS and is the sole property of of BBNS. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://baseballnewssource.com/markets/leerink-swann-begins-coverage-on-nightstar-therapeutics-plc-sponsored-adr-nite/1731359.html.

Several institutional investors and hedge funds have recently modified their holdings of NITE. Ameriprise Financial Inc. bought a new position in shares of Nightstar Therapeutics PLC Sponsored ADR in the 3rd quarter valued at $5,761,000. Chartwell Investment Partners LLC bought a new position in shares of Nightstar Therapeutics PLC Sponsored ADR in the 3rd quarter valued at $3,995,000. Sphera Funds Management LTD. bought a new position in shares of Nightstar Therapeutics PLC Sponsored ADR in the 3rd quarter valued at $1,728,000. Nationwide Fund Advisors bought a new position in shares of Nightstar Therapeutics PLC Sponsored ADR in the 3rd quarter valued at $1,196,000. Finally, Citadel Advisors LLC bought a new position in shares of Nightstar Therapeutics PLC Sponsored ADR in the 3rd quarter valued at $240,000. Institutional investors own 0.23% of the company’s stock.

About Nightstar Therapeutics PLC Sponsored ADR

Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.

Receive News & Ratings for Nightstar Therapeutics PLC Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics PLC Sponsored ADR and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.